LAG-3 in (auto)immunity and cancer - Emphasising its role in antigen presenting cells

Area of Science:

• Immunology
• Oncology

Background:

• Immunotherapy, particularly anti-PD-1 treatment, shows promise for cancer therapy.
• A need exists for novel therapeutics targeting
• immune-cold
• tumors unresponsive to current treatments.

Purpose of the Study:

• To review the role of Lymphocyte Activation Gene-3 (LAG-3) in immune responses.
• To explore LAG-3-directed therapies, including their impact on antigen-presenting cells (APCs) and potential in autoimmunity.
• To provide a balanced perspective on the advantages and disadvantages of LAG-3-based cancer treatments.

Main Methods:

• Literature review focusing on Lymphocyte Activation Gene-3 (LAG-3) as an immune checkpoint (IC) molecule.
• Analysis of two primary therapeutic approaches: anti-LAG-3 antibodies and recombinant soluble LAG-3.
• Examination of LAG-3's physiological role in auto-tolerance and its function on APCs.

Main Results:

• LAG-3 is a significant immune checkpoint molecule involved in auto-tolerance.
• Both anti-LAG-3 antibodies and soluble LAG-3 have demonstrated potential as safe and effective anti-cancer strategies.
• LAG-3's interaction with APCs is crucial for its immune-modulating effects.

Conclusions:

• LAG-3 represents a promising target for novel cancer immunotherapies, particularly for treatment-resistant tumors.
• Understanding LAG-3's dual role in autoimmunity and cancer is essential for optimizing therapeutic strategies.
• Further research into LAG-3-directed therapies could expand treatment options for various cancers.